19. ライソゾーム病 Lysosomal storage disease Clinical trials / Disease details
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01747980 (ClinicalTrials.gov) | March 2013 | 5/12/2012 | Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients | An Exploratory, Open-label Study to Evaluate the Safety of PRX-112 and Pharmacokinetics of Oral prGCD (Plant Recombinant Human Glucocerebrosidase) in Gaucher Patients | Gaucher Disease | Drug: PRX-112 | Protalix | NULL | Completed | 18 Years | N/A | Both | 16 | Phase 1 | Israel |
| 2 | EUCTR2011-003685-32-ES (EUCTR) | 27/01/2012 | 13/10/2011 | NA | A Multicenter Extension Study of Taliglucerase alfa in Adult Subjects with Gaucher Disease - NA | Gaucher disease MedDRA version: 14.0;Level: PT;Classification code 10018048;Term: Gaucher's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: recombinant human glucerebrosidase Product Code: Taliglucerase Alfa INN or Proposed INN: Taliglucerase alfa Other descriptive name: prGCD | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 25 | Phase 3 | Serbia;Mexico;Canada;Spain;South Africa;Israel;Chile;Italy | ||
| 3 | EUCTR2011-003676-37-ES (EUCTR) | 15/11/2011 | 14/09/2011 | NA | A Multicenter Extension Study of Taliglucerase alfa in Pediatric Subjects with Gaucher Disease - NA | Gaucher disease MedDRA version: 14.0;Level: PT;Classification code 10018048;Term: Gaucher's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: recombinant human glucerebrosidase Product Code: Taliglucerase Alfa INN or Proposed INN: Taliglucerase alfa Other descriptive name: prGCD | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 15 | Phase 3 | Spain;South Africa;Israel | ||
| 4 | EUCTR2008-005825-12-GB (EUCTR) | 17/12/2009 | 28/04/2009 | A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NA | A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NA | Gaucher Disease MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease | Product Name: UPLYSO Product Code: Taliglucerase alfa Other descriptive name: recombinant human glucocerebrosidase (prGCD) | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Spain;Germany;Italy;United Kingdom | ||
| 5 | EUCTR2008-005825-12-DE (EUCTR) | 10/12/2009 | 16/09/2009 | A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NA | A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NA | Gaucher Disease MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease | Product Name: UPLYSO Product Code: Taliglucerase alfa INN or Proposed INN: Taliglucerase alfa Other descriptive name: Recombinant Human Glucocerebrosidase (prGCD) | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 3 | Spain;Germany;Italy;United Kingdom | ||
| 6 | EUCTR2008-005825-12-IT (EUCTR) | 28/07/2009 | 16/09/2009 | : A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme) Enzyme Replacement Therapy - PB-06-002 | : A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme) Enzyme Replacement Therapy - PB-06-002 | Gaucher disease MedDRA version: 9.1;Level: SOC;Classification code 10029205 | Product Name: Plant Cell Recombinant Glucocerebrosidase Product Code: prGCD | PROTALIX BIOTHERAPEUTICS | NULL | Not Recruiting | Female: yes Male: yes | 15 | Phase 3 | Germany;United Kingdom;Spain;Italy | ||
| 7 | EUCTR2008-005826-35-GB (EUCTR) | 24/06/2009 | 14/04/2009 | A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease | A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease | Gaucher Disease MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease | Product Name: UPLYSO Product Code: Taliglucerase alfa Other descriptive name: recombinant human glucocerebrosidase (prGCD) Product Name: UPLYSO Product Code: Taliglucerase alfa Other descriptive name: recombinant human glucocerebrosidase (prGCD) | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Spain;Italy;United Kingdom | ||
| 8 | EUCTR2008-005826-35-IT (EUCTR) | 19/06/2009 | 30/06/2009 | A multicenter, double-blind, extension trial of two parallel dose groups of Plant cell expressed recombinant human glucocerebrosidase (prGCD) in patients with Gaucher disiease. - PB-06-003 | A multicenter, double-blind, extension trial of two parallel dose groups of Plant cell expressed recombinant human glucocerebrosidase (prGCD) in patients with Gaucher disiease. - PB-06-003 | Gaucher Disease | Product Name: Plant Cell Recombinant Glucocerebrosidase Product Code: prGCD Product Name: Plant Cell Recombinant Glucocerebrosidase Product Code: prGCD | PROTALIX BIOTHERAPEUTICS | NULL | Not Recruiting | Female: yes Male: yes | 30 | United Kingdom;Spain;Italy | |||
| 9 | EUCTR2008-005825-12-ES (EUCTR) | 04/06/2009 | 06/03/2009 | Ensayo clinico de fase 3, multicéntrico, en abierto y con cambio de tratamiento para evaluar la seguridad y eficacia de Glucocerebrosidasa Humana Recombinante expresada en células vegetales (prGCD) en pacientes con enfermedad de Gaucher tratados con Imiglucerasa (Cerezyme®) como terapia de reemplazo enzimatico. A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NA | Ensayo clinico de fase 3, multicéntrico, en abierto y con cambio de tratamiento para evaluar la seguridad y eficacia de Glucocerebrosidasa Humana Recombinante expresada en células vegetales (prGCD) en pacientes con enfermedad de Gaucher tratados con Imiglucerasa (Cerezyme®) como terapia de reemplazo enzimatico. A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NA | Enfermedad de GaucherGaucher Disease MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease | Product Name: recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: recombinant human glucocerebrosidase | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 15 | Phase 3 | Germany;United Kingdom;Spain;Italy | ||
| 10 | EUCTR2008-005826-35-ES (EUCTR) | 04/06/2009 | 07/04/2009 | Ensayo clínico de extensión, multicéntrico, doble ciego con dos grupos paralelos de dosis de glucocerebrosidasa humana recombinante expresada en células vegetales (prGCD) en pacientes con enfermedad de Gaucher A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease | Ensayo clínico de extensión, multicéntrico, doble ciego con dos grupos paralelos de dosis de glucocerebrosidasa humana recombinante expresada en células vegetales (prGCD) en pacientes con enfermedad de Gaucher A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease | Enfermedad de GaucherGaucher Disease MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease | Product Name: recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: recombinant human glucocerebrosidase Product Name: recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: recombinant human glucocerebrosidase | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 3 | Spain;Italy;United Kingdom | ||
| 11 | EUCTR2007-000498-42-IT (EUCTR) | 13/11/2008 | 19/03/2009 | A phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two parallel Dose Groups of Plant CElle Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease - ND | A phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two parallel Dose Groups of Plant CElle Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease - ND | Gaucher Disease MedDRA version: 9.1;Level: LLT;Classification code 10018048;Term: Gaucher's disease | Product Name: Plant Cell Recombinant Glucocerebrosidase Product Code: prGCD INN or Proposed INN: GLUCOCEREBROSIDASE Product Name: Plant Cell Recombinant Glucocerebrosidase Product Code: prGCD INN or Proposed INN: GLUCOCEREBROSIDASE | PROTALIX BIOTHERAPEUTICS | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 3 | United Kingdom;Spain;Italy | ||
| 12 | EUCTR2007-000498-42-ES (EUCTR) | 08/10/2008 | 10/07/2008 | Ensayo clinico de fase III, multicéntrico, aleatorizado, doble ciego; para evaluar la seguridad y eficacia de dos grupos paralelos de dosis de glucocerebrosidasa humana recombinante expresada en células vegetales (prGCD) en pacientes con enfermedad de Gaucher.A phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease. - NA | Ensayo clinico de fase III, multicéntrico, aleatorizado, doble ciego; para evaluar la seguridad y eficacia de dos grupos paralelos de dosis de glucocerebrosidasa humana recombinante expresada en células vegetales (prGCD) en pacientes con enfermedad de Gaucher.A phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease. - NA | Enfermedad de Gaucher.Gaucher disease. MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease | Product Name: recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: recombinant human glucocerebrosidase Product Name: recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: recombinant human glucocerebrosidase | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 3 | Spain;Italy;United Kingdom | ||
| 13 | NCT00705939 (ClinicalTrials.gov) | June 2008 | 25/6/2008 | Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial | A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease | Gaucher Disease | Drug: Taliglucerase alfa | Pfizer | NULL | Completed | 18 Years | N/A | All | 45 | Phase 3 | United States;Australia;Canada;Chile;Israel;South Africa;Spain;United Kingdom |
| 14 | EUCTR2007-000498-42-GB (EUCTR) | 08/05/2008 | 07/01/2008 | A Phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease - NA | A Phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease - NA | Gaucher disease MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease | Product Name: recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: recombinant human glucocerebrosidase Product Name: recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: recombinant human glucocerebrosidase | Protalix Biotherapeutics | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Spain;Italy;United Kingdom | ||
| 15 | NCT00376168 (ClinicalTrials.gov) | August 2007 | 12/9/2006 | A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease | A Phase III, Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease | Gaucher Disease | Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Pfizer | NULL | Completed | 18 Years | N/A | All | 32 | Phase 3 | United States;Canada;Chile;Israel;Italy;South Africa;Spain;United Kingdom |
| 16 | NCT00962260 (ClinicalTrials.gov) | July 2006 | 18/8/2009 | Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease | An Open-label Expanded Access Trial of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease Who Require Enzyme Replacement Therapy | Gaucher Disease | Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Pfizer | NULL | No longer available | 18 Years | N/A | All | United States;Israel | ||
| 17 | NCT00258778 (ClinicalTrials.gov) | November 2005 | 23/11/2005 | Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) | A Phase I, Non-Randomized, Open Label, Single Dose-Escalation Safety Study of Recombinant Human Glucocerebrosidase (prGCD) in Healthy Volunteers | Gaucher Disease | Drug: Human Glucocerebrosidase (prGCD) | Protalix | NULL | Completed | 18 Years | 45 Years | Both | 6 | Phase 1 | Israel |
| 18 | EUCTR2007-000498-42-Outside-EU/EEA (EUCTR) | 10/04/2012 | A double-blind, randomised efficacy and safety study of taliglucerase alfa enzyme replacement therapy in children and adolescents with Gaucher disease (non-neuronopathic and chronic neuronopathic) | A double-blind, randomised efficacy and safety study of taliglucerase alfa enzyme replacement therapy in children and adolescents with Gaucher disease (non-neuronopathic and chronic neuronopathic) | Gaucher disease MedDRA version: 14.1;Level: PT;Classification code 10018048;Term: Gaucher's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Taliglucerase alfa - Recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: TALIGLUCERASE ALFA | Protalix Biotherapeutics | NULL | NA | Female: yes Male: yes | 10 | Israel;United States | ||||
| 19 | EUCTR2008-005825-12-Outside-EU/EEA (EUCTR) | 10/04/2012 | A multi-centre, open-label, switchover trial to assess safety and efficacy of taliglucerase alfa in adult and paediatric patients with Gaucher disease who are currently being treated with imiglucerase enzyme replacement therapy (ERT). | A multi-centre, open-label, switchover trial to assess safety and efficacy of taliglucerase alfa in adult and paediatric patients with Gaucher disease who are currently being treated with imiglucerase enzyme replacement therapy (ERT). | Gaucher disease MedDRA version: 14.1;Level: PT;Classification code 10018048;Term: Gaucher's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Taliglucerase alfa - Recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: TALIGLUCERASE ALFA | Protalix Biotherapeutics | NULL | NA | Female: yes Male: yes | 30 | Canada;Israel;United Kingdom;United States | ||||
| 20 | EUCTR2008-005826-35-Outside-EU/EEA (EUCTR) | 10/04/2012 | A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease | A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease | Gaucher disease MedDRA version: 14.1;Level: PT;Classification code 10018048;Term: Gaucher's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Taliglucerase alfa - Recombinant human glucocerebrosidase Product Code: prGCD Other descriptive name: TALIGLUCERASE ALFA | Protalix Biotherapeutics | NULL | NA | Female: yes Male: yes | 30 | Australia;Canada;Chile;Israel;South Africa;Spain;United Kingdom;United States |